HAYWARD, Calif., January 21, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

In this article, learn about arcus senilis. What are the risk factors, how is it diagnosed, how is it linked to high cholesterol, and can it be treated? Learn more.

Arcus Hunting, a Bregal Partners company, acquires Obsession Archery, Inc., an award-winning designer and manufacturer of premium bows.

Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing ...

Gilead Sciences and Arcus Biosciences announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.

HAYWARD, Calif., November 06, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...